SCOTTSDALE, Ariz., Oct. 16, 2025 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation’s largest providers of outpatient mental health care, will issue its third quarter 2025 earnings release before the market opens on Thursday, November 6, 2025. LifeStance will host a live earnings conference call to discuss third quarter results on November 6, 2025, at 8:30 a.m. Eastern Time. To participate in the call, please dial 1-800-715-9871, domestically, or 1-646-307-1963, internationa ...

Vancouver, British Columbia--(Newsfile Corp. - October 10, 2025) -  Numinus Wellness Inc. (TSX: NUMI) (OTCQB: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, announces that Davidson & Company LLP ("Davidson") has resigned as the Company's independent auditor of its own initiative, and that MNP LLP ("MNP") has been engaged as the Company's new independent auditor. Regardl ...

Core Insights - The Oncology Institute (TOI) has partnered with Protocol Behavioral Health to integrate mental health services into cancer care, emphasizing whole-person care [1][2][3] Partnership Overview - The collaboration aims to provide timely access to mental health services for cancer patients, addressing emotional and psychological challenges without waitlists [2][3] - Protocol Behavioral Health's approach ensures that mental health care is a core part of the treatment plan from the beginning [4] Patient Impact - Approximately 30% of cancer patients experience significant depression or anxiety, and behavioral health support is recognized as beneficial for nearly all patients [2] - The integration of behavioral health services is expected to improve treatment adherence, quality of life, and patient satisfaction [6] Operational Model - The partnership utilizes the Collaborative Care Model (CoCM), which integrates behavioral health managers and psychiatric providers into oncology care teams [5][6] - This model facilitates seamless coordination and personalized support for patients throughout their cancer journey [5][6] Company Background - The Oncology Institute, founded in 2007, provides specialized, value-based cancer care to approximately 1.9 million patients across multiple states [4] - Protocol Behavioral Health focuses on evidence-based mental health care tailored to the unique needs of cancer patients [5]

Core Viewpoint - LifeStance Health Group, Inc. is one of the largest providers of outpatient mental health care in the United States and will present at the 23rd Annual Morgan Stanley Global Healthcare Conference in New York City on September 9, 2025 [1][2]. Company Overview - LifeStance Health was founded in 2017 and focuses on reimagining mental health care, providing both virtual and in-person outpatient services for various mental health conditions [4]. - The company employs approximately 7,700 professionals, including psychiatrists, advanced practice nurses, psychologists, and therapists, operating across 33 states with over 550 centers [4]. - LifeStance's mission is to enhance access to trusted, affordable, and personalized mental health care, aiming to help individuals lead healthier and more fulfilling lives [4]. Presentation Details - The presentation will be led by CEO Dave Bourdon and CFO Ryan McGroarty, moderated by Craig Hettenbach, and will take place at 10:00 a.m. Eastern time [2]. - The event will be webcast live and available for replay on the LifeStance Health Investor Relations website [2][3].

Core Insights - LifeStance Health has appointed Sarah Personette to its board of directors, effective immediately, while William Miller will step down after five years of service [1][2][3] Company Overview - LifeStance Health, founded in 2017, is one of the largest providers of outpatient mental health care in the U.S., offering both virtual and in-person services [3] - The company employs approximately 7,700 mental health professionals and operates over 550 centers across 33 states [3] Leadership Changes - Sarah Personette brings over 20 years of experience in customer experience and media, having held significant roles at Puck, X (formerly Twitter), and Refinery29 [2] - The CEO of LifeStance, Dave Bourdon, expressed confidence in Personette's ability to enhance patient-centered care [2][3] - William Miller's contributions during his tenure were acknowledged by the board, highlighting his role in advancing the organization's mission [3]

Core Viewpoint - Numinus Wellness Inc. reported significant growth in revenue for Q2 2025, driven by its focus on innovative mental health care and psychedelic-assisted therapies, although it also faced increased costs and operating losses [1][2]. Financial Performance - Total revenue for Q2 2025 reached CAD 1,512,435, marking an 83.8% increase from CAD 822,973 in Q2 2024 [2]. - Cost of revenue surged to CAD 1,007,691, a 175.7% increase from CAD 365,446 in the same quarter last year [2]. - Gross profit was CAD 504,744, reflecting a 10.3% increase from CAD 457,527 in Q2 2024, with a gross profit margin of 33.4%, down from 55.6% [2]. - Operating expenses rose to CAD 9,886,497, an 86.31% increase from CAD 5,306,523 in Q2 2024 [2]. - The company reported a comprehensive loss of CAD 7,705,397, compared to CAD 5,960,437 in the previous year [2]. Balance Sheet and Liquidity - Numinus ended the quarter with cash and cash equivalents amounting to CAD 705,631 [3]. Company Overview - Numinus Wellness Inc. is focused on developing and delivering innovative mental health care solutions, particularly through evidence-based psychedelic-assisted therapies, aiming to transform treatment for conditions like depression, anxiety, and substance use [4].

Core Insights - Numinus Wellness Inc. reported a significant increase in total revenue for Q1 2025, reaching $2,013,779, which represents a 68.3% increase compared to $1,196,629 in Q1 2024 [2] - The company achieved a gross profit of $1,021,157, marking a 121.1% increase from $461,943 in the same quarter last year, with a gross profit margin of 49.3% [2] - Operating expenses decreased by 51.1% to $2,065,596 from $4,226,850 in Q1 2024, contributing to a reduced comprehensive loss of $1,286,464 compared to $4,351,472 in the previous year [2] Financial Performance Metrics - Total Revenue: $2,013,779 for Q1 2025 vs. $1,196,629 for Q1 2024, a 68.3% increase [2] - Cost of Revenue: $992,622 for Q1 2025 vs. $734,686 for Q1 2024, a 35.1% increase [2] - Gross Profit: $1,021,157 for Q1 2025 vs. $461,943 for Q1 2024, a 121.1% increase [2] - Gross Profit Margin: 49.3% for Q1 2025 vs. 38.6% for Q1 2024, an increase of 107 basis points [2] - Operating Expenses: $2,065,596 for Q1 2025 vs. $4,226,850 for Q1 2024, a decrease of 51.1% [2] - Comprehensive Loss: ($1,286,464) for Q1 2025 vs. ($4,351,472) for Q1 2024 [2] Balance Sheet and Liquidity - Numinus ended the quarter with cash and cash equivalents of $2.0 million [3] - The financial statements were prepared in accordance with IFRS and are available on the company's Investor Relations website [3] Company Overview - Numinus Wellness Inc. focuses on innovative mental health care and the development of safe, evidence-based psychedelic-assisted therapies [4] - The company aims to transform mental health treatment by integrating psychedelic-assisted therapies into mainstream clinical practice, targeting conditions such as depression, anxiety, trauma, pain, and substance use [4]

Core Insights - Numinus Wellness Inc. reported a 16.4% increase in consolidated revenues for Q4 2024 compared to Q3 2024, driven by growth in its Cedar Clinical Research and Practitioner Training segments [3][4][15] - The company successfully transitioned to a lean operation, aligning cash flows with overhead costs, and is focused on leveraging growth opportunities in its clinical research and training businesses [3][4] Financial Performance - Total revenue for Q4 2024 was $1,155,936, up from $992,912 in Q3 2024, marking a 16.4% increase [15] - Revenue from Cedar Clinical Research increased by 17.2% to $965,799, while Practitioner Training revenue rose by 12.6% to $190,137 [4][11] - Gross margin improved to 25.3% in Q4 2024, compared to a gross margin loss of 4.6% in Q3 2024 [5][15] - Operating expenditures decreased significantly to $931,198 from $2.9 million in the previous quarter, reflecting ongoing cost containment initiatives [6][15] Operational Highlights - Cedar Clinical Research managed 18 clinical trials with 306 patient appointments in Q4 2024, an increase from 15 trials and 233 appointments in Q3 2024 [9] - The company’s Psychedelic-Assisted Therapy Training Program received approval from the state of Colorado, enhancing its position in the market [16] Corporate Updates - The company completed the sale of its wellness clinic network for US$3.53 million, leading to the classification of this segment as discontinued operations [8][19] - Leadership changes included the appointment of Michael Tan as CEO and Kelvin Yang as CFO [8] Balance Sheet and Liquidity - Numinus ended Q4 2024 with cash and cash equivalents of $2.0 million and working capital of $1.2 million [14]

Core Insights - LifeStance Health Group, Inc. is set to release its second quarter 2025 earnings on August 7, 2025, before market opening [1] - A live earnings conference call will be held on the same day at 8:30 a.m. Eastern Time to discuss the results [2] - The company provides access to a real-time audio webcast of the earnings call on its Investor Relations website [3] Company Overview - Founded in 2017, LifeStance is one of the largest providers of outpatient mental health care in the U.S., offering both virtual and in-person services [4] - The company employs approximately 7,500 mental health professionals and operates over 550 centers across 33 states [4] - LifeStance's mission focuses on improving access to affordable and personalized mental health care for individuals of all ages [4]

Core Insights - LifeStance Health Group, Inc. is one of the largest providers of outpatient mental health care in the United States [3] - The company will present at the 46th Annual Goldman Sachs Healthcare Conference on June 10, 2025 [1] - The presentation will be led by CEO Dave Bourdon and CFO Ryan McGroarty, and will be available via live webcast [1][2] Company Overview - LifeStance Health was founded in 2017 and focuses on providing virtual and in-person outpatient mental health care for various age groups [3] - The company employs approximately 7,500 mental health professionals and operates over 550 centers across 33 states [3] - LifeStance aims to improve access to affordable and personalized mental health care, helping individuals lead healthier lives [3]